Patents by Inventor Dana Borden Lacy

Dana Borden Lacy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High-throughput, multi-omics approach to determine and validate de novo global mechanisms of action for drugs and toxins
    Patent number: 10607721
    Abstract: The present disclosure provides for rapid identification of mechanism of action (MOA) for drugs and toxins, and does so in a rapid (30 days or less) fashion. The methods use a combination of high throughput bioinformatics and pathway analysis that examine a wide variety of biological parametics.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: March 31, 2020
    Assignee: VANDERBILT UNIVERSITY
    Inventors: Richard Caprioli, John Wikswo, John McLean, Eric Skaar, Jeremy L. Norris, Dana Borden Lacy, Stacy Sherrod, James Pino, Danielle Gutierrez, Nicole D. Muszynski, Melissa Farrow
  • Mammalian genes involved in toxicity and infection
    Patent number: 10202615
    Abstract: The present invention relates to cellular proteins that are involved in toxicity and infection or are otherwise associated with the life cycle of one or more pathogens.
    Type: Grant
    Filed: December 11, 2011
    Date of Patent: February 12, 2019
    Assignee: VANDERBILT UNIVERSITY
    Inventors: Donald Rubin, Dana Borden Lacy
  • Compositions and methods for treating or preventing infection
    Patent number: 9926345
    Abstract: Clostridium difficile is a leading cause of antibiotic-associated infection in hospitals worldwide. There is a need for a vaccine to Clostridium difficile that can target toxic proteins, or that can elicit adequate immunity to prevent infection or reduce the severity of infection. Modified Clostridium difficile toxin A and B (TcdA and TcdB) proteins are described herein, which comprise mutations that reduce toxin A and B toxicity compared to the native toxin. The proteins described are highly similar to the native toxin of Clostridium difficile, but toxicity is reduced.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: March 27, 2018
    Assignees: THE HOSPITAL FOR SICK CHILDREN, VANDERBILT UNIVERSITY
    Inventors: Roman Melnyk, Zhifen Zhang, John Tam, Dana Borden Lacy, Stacey A. Seeback, Nicole M. Chumbler
  • COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CLOSTRIDIUM INFECTION
    Publication number: 20170008937
    Abstract: Clostridium difficile is a leading cause of antibiotic-associated infection in hospitals worldwide. There is a need for a vaccine to Clostridium difficile that can target toxic proteins, or that can elicit adequate immunity to prevent infection or reduce the severity of infection. Modified Clostridium difficile toxin A and B (TcdA and TcdB) proteins are described herein, which comprise mutations that reduce toxin A and B toxicity compared to the native toxin. The proteins described are highly similar to the native toxin of Clostridium difficile, but toxicity is reduced.
    Type: Application
    Filed: February 17, 2015
    Publication date: January 12, 2017
    Inventors: Roman MELNYK, Zhifen ZHANG, John TAM, Dana Borden LACY, Stacey A. SEEBACK, Nicole M. CHUMBLER
  • MAMMALIAN GENES INVOLVED IN TOXICITY AND INFECTION
    Publication number: 20140242692
    Abstract: The present invention relates to cellular proteins that are involved in toxicity and infection or are otherwise associated with the life cycle of one or more pathogens.
    Type: Application
    Filed: December 11, 2011
    Publication date: August 28, 2014
    Inventors: Donald Rubin, Dana Borden Lacy